As cells age, mitochondria can become less efficient, leading to a decline in overall cellular function
At the molecular level, 5-amino-1MQ functions as a competitive inhibitor of NNMT, demonstrating remarkable potency with an IC of 1.2 0.1 M under standard assay conditions (50 M SAM, 100 M nicotinic acid). This represents a dramatic 10-fold improvement over the parent compound 1-methylquinolinium, achieved through strategic amino group substitution that enhances binding affinity to the NNMT active site. The compound's mechanism centers on preventing the methylation of nicotinamide to 1-methylnicotinamide (1-MNA), thereby preserving nicotinamide for recycling back to NAD+ through the salvage pathway. This intervention effectively blocks what researchers have termed the "NNMT metabolic drain" a process that simultaneously depletes NAD+ precursors and consumes cellular methylation capacity
This higher dose can be administered as a single 100mg injection in the morning or split into two 50mg doses taken 12 hours apart (morning and afternoon)
Phase Weeks 3+ (higher end) Daily dose 150 mg once daily Notes Some sources go this high
Commonly reported issues include mild gastrointestinal discomfort, particularly when starting the compound, and temporary headaches during the adjustment period
